Search Results - "Attard, G."

Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial by Clarke, N.W., Ali, A., Ingleby, F.C., Hoyle, A., Amos, C.L., Attard, G., Brawley, C.D., Calvert, J., Chowdhury, S., Cook, A., Cross, W., Dearnaley, D.P., Douis, H., Gilbert, D., Gillessen, S., Jones, R.J., Langley, R.E., MacNair, A., Malik, Z., Mason, M.D., Matheson, D., Millman, R., Parker, C.C., Ritchie, A.W.S., Rush, H., Russell, J.M., Brown, J., Beesley, S., Birtle, A., Capaldi, L., Gale, J., Gibbs, S., Lydon, A., Nikapota, A., Omlin, A., O'Sullivan, J.M., Parikh, O., Protheroe, A., Rudman, S., Srihari, N.N., Simms, M., Tanguay, J.S., Tolan, S., Wagstaff, J., Wallace, J., Wylie, J., Zarkar, A., Sydes, M.R., Parmar, M.K.B., James, N.D.

“…STAMPEDE has previously reported that the use of upfront docetaxel improved overall survival (OS) for metastatic hormone naïve prostate cancer patients…”
Get full text

Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100) by Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., Albiges, L., Attard, G., Fizazi, K., De Bono, J.S., Massard, C.

“…Androgen receptor (AR) signalling remains critically important in metastatic castration-resistant prostate cancer (mCRPC) as confirmed by recent phase III…”
Get full text

Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects by Ferraldeschi, R, Welti, J, Luo, J, Attard, G, de Bono, J S

“…Androgen receptor (AR) signaling is a critical pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for…”
Get full text

Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse by Taavitsainen, S., Engedal, N., Cao, S., Handle, F., Erickson, A., Prekovic, S., Wetterskog, D., Tolonen, T., Vuorinen, E. M., Kiviaho, A., Nätkin, R., Häkkinen, T., Devlies, W., Henttinen, S., Kaarijärvi, R., Lahnalampi, M., Kaljunen, H., Nowakowska, K., Syvälä, H., Bläuer, M., Cremaschi, P., Claessens, F., Visakorpi, T., Tammela, T. L. J., Murtola, T., Granberg, K. J., Lamb, A. D., Ketola, K., Mills, I. G., Attard, G., Wang, W., Nykter, M., Urbanucci, A.

“…Prostate cancer is heterogeneous and patients would benefit from methods that stratify those who are likely to respond to systemic therapy. Here, we employ…”
Get full text

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group by Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J.D., Montagut, C., Normanno, N., Pantel, K., Pentheroudakis, G., Popat, S., Reis-Filho, J.S., Tie, J., Seoane, J., Tarazona, N., Yoshino, T., Turner, N.C.

“…Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a strong evidence base for use in patients with cancer. The European Society…”
Get full text

Unexpectedly uneven distribution of functional trade-offs explains cranial morphological diversity in carnivores by Sansalone, Gabriele, Wroe, Stephen, Coates, Geoffrey, Attard, Marie R. G., Fruciano, Carmelo

“…Functional trade-offs can affect patterns of morphological and ecological evolution as well as the magnitude of morphological changes through evolutionary…”
Get full text

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial by Chi, K.N., Sandhu, S., Smith, M.R., Attard, G., Saad, M., Olmos, D., Castro, E., Roubaud, G., Pereira de Santana Gomes, A.J., Small, E.J., Rathkopf, D.E., Gurney, H., Jung, W., Mason, G.E., Dibaj, S., Wu, D., Diorio, B., Urtishak, K., del Corral, A., Francis, P., Kim, W., Efstathiou, E.

“…Patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA alterations have poor outcomes. MAGNITUDE found patients with homologous…”
Get full text

Prostate cancers that ‘Wnt’ respond to abiraterone by Linch, M., Attard, G.

Get full text

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol by Sydes, M.R., Spears, M.R., Mason, M.D., Clarke, N.W., Dearnaley, D.P., de Bono, J.S., Attard, G., Chowdhury, S., Cross, W., Gillessen, S., Malik, Z.I., Jones, R., Parker, C.C., Ritchie, A.W.S., Russell, J.M., Millman, R., Matheson, D., Amos, C., Gilson, C., Birtle, A., Brock, S., Capaldi, L., Chakraborti, P., Choudhury, A., Evans, L., Ford, D., Gale, J., Gibbs, S., Gilbert, D.C., Hughes, R., McLaren, D., Lester, J.F., Nikapota, A., O’Sullivan, J., Parikh, O., Peedell, C., Protheroe, A., Rudman, S.M., Shaffer, R., Sheehan, D., Simms, M., Srihari, N., Strebel, R., Sundar, S., Tolan, S., Tsang, D., Varughese, M., Wagstaff, J., Parmar, M.K.B., James, N.D.

“…Adding abiraterone acetate with prednisolone (AAP) or docetaxel with prednisolone (DocP) to standard-of-care (SOC) each improved survival in systemic therapy…”
Get full text

Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial by Jayaram, A., Wingate, A., Wetterskog, D., Wheeler, G., Sternberg, C.N., Jones, R., Berruti, A., Lefresne, F., Lahaye, M., Thomas, S., Gormley, M., Meacham, F., Garg, K., Lim, L.P., Merseburger, A.S., Tombal, B., Ricci, D., Attard, G.

“…Plasma tumor DNA fraction is prognostic in metastatic cancers. This could improve risk stratification before commencing a new treatment. We hypothesized that a…”
Get full text

Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone by Bianchini, D, Lorente, D, Rodriguez-Vida, A, Omlin, A, Pezaro, C, Ferraldeschi, R, Zivi, A, Attard, G, Chowdhury, S, de Bono, J.S

“…Abstract Background The new generation anti-androgen enzalutamide and the potent CYP17 inhibitor abiraterone have both demonstrated survival benefits in…”
Get full text

Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study by Conteduca, V., Wetterskog, D., Sharabiani, M.T.A., Grande, E., Fernandez-Perez, M.P., Jayaram, A., Salvi, S., Castellano, D., Romanel, A., Lolli, C., Casadio, V., Gurioli, G., Amadori, D., Font, A., Vazquez-Estevez, S., González del Alba, A., Mellado, B., Fernandez-Calvo, O., Méndez-Vidal, M.J., Climent, M.A., Duran, I., Gallardo, E., Rodriguez, A., Santander, C., Sáez, M.I., Puente, J., Gasi Tandefelt, D., Wingate, A., Dearnaley, D., Demichelis, F., De Giorgi, U., Gonzalez-Billalabeitia, E., Attard, G.

“…There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify…”
Get full text

Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 by Gillessen, S., Omlin, A., Attard, G., de Bono, J.S., Efstathiou, E., Fizazi, K., Halabi, S., Nelson, P.S., Sartor, O., Smith, M.R., Soule, H.R., Akaza, H., Beer, T.M., Beltran, H., Chinnaiyan, A.M., Daugaard, G., Davis, I.D., De Santis, M., Drake, C.G., Eeles, R.A., Fanti, S., Gleave, M.E., Heidenreich, A., Hussain, M., James, N.D., Lecouvet, F.E., Logothetis, C.J., Mastris, K., Nilsson, S., Oh, W.K., Olmos, D., Padhani, A.R., Parker, C., Rubin, M.A., Schalken, J.A., Scher, H.I., Sella, A., Shore, N.D., Small, E.J., Sternberg, C.N., Suzuki, H., Sweeney, C.J., Tannock, I.F., Tombal, B.

“…The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed the available evidence for the ten most…”
Get full text

Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone by Salvi, S, Casadio, V, Conteduca, V, Burgio, S L, Menna, C, Bianchi, E, Rossi, L, Carretta, E, Masini, C, Amadori, D, Calistri, D, Attard, G, De Giorgi, U

“…Background: This study aimed to investigate copy number variations (CNVs) of CYP17A1 and androgen receptor ( AR ) genes in serum cell-free DNA collected before…”
Get full text

Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer by Attard, G, Clark, J, Ambroisine, L, Fisher, G, Kovacs, G, Flohr, P, Berney, D, Foster, C S, Fletcher, A, Gerald, W L, Moller, H, Reuter, V, De Bono, J S, Scardino, P, Cuzick, J, Cooper, C S

“…New predictive markers for managing prostate cancer are urgently required because of the highly variable natural history of this disease. At the time of…”
Get full text

Prioritizing precision medicine for prostate cancer by Attard, G., Beltran, H.

Get full text

Diagnostic Gleason score and castration-resistant prostate cancer by Jayaram, A., Attard, G.

Get full text

Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial by Hamid, A.A., Huang, H.-C., Wang, V., Chen, Y.-H., Feng, F., Den, R., Attard, G., Van Allen, E.M., Tran, P.T., Spratt, D.E., Dittamore, R., Davicioni, E., Liu, G., DiPaola, R., Carducci, M.A., Sweeney, C.J.

“…The phase III CHAARTED trial established upfront androgen-deprivation therapy (ADT) plus docetaxel (D) as a standard for metastatic hormone-sensitive prostate…”
Get full text

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? by Mezynski, J., Pezaro, C., Bianchini, D., Zivi, A., Sandhu, S., Thompson, E., Hunt, J., Sheridan, E., Baikady, B., Sarvadikar, A., Maier, G., Reid, A.H.M., Mulick Cassidy, A., Olmos, D., Attard, G., de Bono, J.

“…Abiraterone and docetaxel are both approved treatments for men with metastatic castration-resistant prostate cancer (mCRPC). Abiraterone pre-docetaxel is…”
Get full text

Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters by Linch, M., Goh, G., Hiley, C., Shanmugabavan, Y., McGranahan, N., Rowan, A., Wong, Y.N.S., King, H., Furness, A., Freeman, A., Linares, J., Akarca, A., Herrero, J., Rosenthal, R., Harder, N., Schmidt, G., Wilson, G.A., Birkbak, N.J., Mitter, R., Dentro, S., Cathcart, P., Arya, M., Johnston, E., Scott, R., Hung, M., Emberton, M., Attard, G., Szallasi, Z., Punwani, S., Quezada, S.A., Marafioti, T., Gerlinger, M., Ahmed, H.U., Swanton, C.

“…Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm,…”
Get full text